What is FibriCheck?
FibriCheck is a health technology company dedicated to making healthcare universally accessible, irrespective of time or location. The company's core focus is on the early detection of heart rhythm disorders, with a primary emphasis on atrial fibrillation (Afib), a condition that can lead to strokes. Leveraging clinically validated photoplethysmography (PPG) technology, FibriCheck's CE-marked application enables users to monitor their heart rhythm using only a smartphone or smartwatch, eliminating the need for additional hardware. This at-home solution has already assisted over 130,000 individuals across 43 countries and has been prescribed by more than 1,500 doctors, facilitating the identification of over 14,000 heart rhythm irregularities to date. The company's approach positions it as a key player in preventative cardiology and remote patient monitoring.
How much funding has FibriCheck raised?
FibriCheck has raised a total of $1.6M across 1 funding round:
Series A
$1.6M
Series A (2017): $1.6M with participation from Volta Ventures and LRM Investment Fund
Key Investors in FibriCheck
Volta Ventures
Volta Ventures is a venture capital firm specializing in seed and early-stage investments in enterprise software startups within the Benelux region. They focus on B2B SaaS companies, providing strategic backing to accelerate growth.
LRM Investment Fund
LRM Investment Fund is an investment entity that participated in FibriCheck's funding round. Further details on their specific investment focus are not publicly available.
What's next for FibriCheck?
The recent major strategic investment in FibriCheck signals a pivotal moment for the company, likely enabling accelerated expansion of its user base and further development of its diagnostic capabilities. With a strong foundation in CE-marked technology and a growing global presence, FibriCheck is well-positioned to capitalize on the increasing demand for accessible, remote health monitoring solutions. Future growth may involve strategic partnerships with healthcare providers, insurance companies, and device manufacturers to integrate its technology more deeply into existing healthcare ecosystems and explore new therapeutic areas beyond Afib detection. The company's trajectory suggests a move towards scaling its operations and solidifying its market leadership in digital cardiology.
See full FibriCheck company page
